MedPage Today

In Spinal Muscular Atrophy, What Factors Influence Pain in Which Patients?

"Managing pain in patients with SMA begins with the recognition that there are predictable etiologies leading to pain in SMA and investigating them during each medical visit is important to implement ...
News Medical

Nusinersen treatment improves spinal muscular atrophy patients’ walking distance

A positive effect of nusinersen treatment on motor function in ambulant pediatric and adult spinal muscular atrophy (SMA) patients during a 38-month period has been demonstrated by an analysis of data ...

The six ‘red flag’ signs of Spinal Muscular Atrophy you need to know – as Jesy Nelson reveals her baby twins’ diagnosis

LITTLE Mix star Jesy Nelson has revealed that her baby twins have been diagnosed with a severe form of Spinal Muscular ...
The American Journal of Managed Care

Bridging the Gap: Addressing Unmet Needs in Spinal Muscular Atrophy for Older Patients

Panelists discuss how the current spinal muscular atrophy (SMA) treatment landscape includes 3 options: gene therapy (onasemnogene abeparvovec [Zolgensma]) for younger patients and 2 splice modifiers ...
Morningstar

Cure SMA Welcomes Broad FDA Approval of Itvisma™ for Spinal Muscular Atrophy, Reinforces Commitment to Patient Access and Support

SCHAUMBURG, Ill., Nov. 26, 2025 /PRNewswire/ -- Cure SMA, the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of ...

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and ...
GEN

Base Editing Strategy for Spinal Muscular Atrophy Rescues Patient Fibroblasts, Reverses Mouse Pathology

A new study describes a base editing method for treating spinal muscular atrophy (SMA). This supports early signs that “single-shot” treatments from clinical trials using genome editing technologies ...
MedPage Today

In Spinal Muscular Atrophy, Assess Mandibular Dysfunction Frequently

"Decreasing AMMO [active maximal mouth opening] over time is seen most often in patients with SMA type 2 with an estimated reduction of almost 1 mm per year...At this point, we propose that ...
STAT

Scholar Rock drug for spinal muscular atrophy succeeds in late-stage study

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. The biotech company ...
EurekAlert!

Spinal muscular atrophy patients’ walking distance improved after Nusinersen treatment

Amsterdam, February 14, 2023 – A positive effect of nusinersen treatment on motor function in ambulant pediatric and adult spinal muscular atrophy (SMA) patients during a 38-month period has been ...
MarketWatch

Cure SMA Welcomes Broad FDA Approval of Itvisma(TM) for Spinal Muscular Atrophy, Reinforces Commitment to Patient Access and Support

The MarketWatch News Department was not involved in the creation of this content. SCHAUMBURG, Ill., Nov. 26, 2025 /PRNewswire/ -- Cure SMA, the leading nonprofit organization dedicated to supporting ...